Q2 EPS Estimates for Pyxis Oncology Cut by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Research analysts at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for shares of Pyxis Oncology in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.36) for the quarter, down from their prior estimate of ($0.31). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.55) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($0.60) EPS.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06).

Separately, Royal Bank of Canada restated an “outperform” rating and set a $8.00 price objective on shares of Pyxis Oncology in a research report on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Pyxis Oncology Trading Down 5.0%

Shares of PYXS opened at $1.15 on Wednesday. The business’s 50-day moving average price is $1.06 and its 200 day moving average price is $1.59. The stock has a market capitalization of $71.24 million, a P/E ratio of -1.12 and a beta of 1.15. Pyxis Oncology has a 1-year low of $0.83 and a 1-year high of $5.39.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PYXS. Barclays PLC raised its stake in shares of Pyxis Oncology by 275.0% in the 3rd quarter. Barclays PLC now owns 64,089 shares of the company’s stock valued at $235,000 after acquiring an additional 46,997 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in shares of Pyxis Oncology by 61.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock valued at $41,000 after acquiring an additional 10,000 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Pyxis Oncology by 88.1% in the 4th quarter. American Century Companies Inc. now owns 299,937 shares of the company’s stock valued at $468,000 after acquiring an additional 140,498 shares in the last quarter. Sei Investments Co. bought a new position in shares of Pyxis Oncology in the 4th quarter valued at approximately $95,000. Finally, Aristides Capital LLC bought a new position in shares of Pyxis Oncology in the 4th quarter valued at approximately $193,000. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.